Tumour suppressor CYLD is a negative regulator of the mitotic kinase Aurora-B

Journal of Pathology

Volumn 221, Issue 4, 2010, Pages 425-432

  Sun, Lei ^a   Gao, Jinmin ^a   Huo, Lihong ^a   Sun, Xiaoou ^a   Shi, Xingjuan ^a   Liu, Min ^a   Li, Dengwen ^a   Zhang, Chuanmao ^b   Zhou, Jun ^a  

^a NANKAI UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Aurora B; CYLD; Deubiquitinase; Kinase activity; PP2A

Indexed keywords

AURORA B KINASE; PHOSPHOPROTEIN PHOSPHATASE 2A;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; CLINICAL ASSESSMENT; CYLD GENE; ENZYME REPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DNA INTERACTION; REGULATOR GENE; TUMOR SUPPRESSOR GENE;

CELLS, CULTURED; GENE KNOCKDOWN TECHNIQUES; HELA CELLS; HUMANS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 77955506844     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2723     Document Type: Article

References (30)

1. van Balkom ID, Hennekam RC. Dermal eccrine cylindromatosis. J Med Genet 1994; 31: 321-324.
2. Bignell GR, Warren W, Seal S, et al. Identification of the familial cylindromatosis tumour-suppressor gene. Nature Genet 2000; 25: 160-165.
3. Sun SC. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ 2010; 17: 25-34.
4. Kovalenko A, Chable-Bessia C, Cantarella G, et al. The tumour suppressor CYLD negatively regulates NF-kappa B signalling by deubiquitination. Nature 2003; 424: 801-805.
5. Regamey A, Hohl D, Liu JW, et al . The tumor suppressor CYLD interacts with TRIP and regulates negatively nuclear factor kappa B activation by tumor necrosis factor. J Exp Med 2003; 198: 1959-1964.
6. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappa B activation by TNFR family members. Nature 2003; 424: 793-796.
7. Massoumi R, Chmielarska K, Hennecke K, et al . Cyld inhibits tumor cell proliferation by blocking Bcl-3-dependent NF-kappaB signaling. Cell 2006; 125: 665-677.
8. Reiley W, Zhang M, Sun SC. Negative regulation of JNK signaling by the tumor suppressor CYLD. J Biol Chem 2004; 279: 55161-55167.
9. Ikeda F, Dikic I. CYLD in ubiquitin signaling and tumor pathogenesis. Cell 2006; 125: 643-645.
10. Gao J, Huo L, Sun X, et al. The tumor suppressor CYLD regulates microtubule dynamics and plays a role in cell migration. J Biol Chem 2008; 283: 8802-8809.
11. Stegmeier F, Sowa ME, Nalepa G, et al. The tumor suppressor CYLD regulates entry into mitosis. Proc Natl Acad Sci U S A 2007; 104: 8869-8874.
12. Jin W, Chang M, Paul EM, et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008; 118: 1858-1866.
13. Reiley WW, Zhang M, Jin W, et al. Regulation of T cell development by the deubiquitinating enzyme CYLD. Nature Immunol 2006; 7: 411-417.
14. Gao J, Sun L, Huo L, et al. CYLD regulates angiogenesis by mediating vascular endothelial cell migration. Blood 2010; DOI:10.1182/blood-2009-10- 248526.
15. Sun L, Gao J, Dong X, et al. EB1 promotes Aurora-B kinase activity through blocking its inactivation by protein phosphatase 2A. Proc Natl Acad Sci U S A 2008; 105: 7153-7158.
16. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nature Rev Mol Cell Biol 2007; 8: 798-812.
17. Tatsuka M, Katayama H, Ota T, et al. Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 1998; 58: 4811-4816.
18. Terada Y, Tatsuka M, Suzuki F, et al. AIM-1: a mammalian midbody-associated protein required for cytokinesis. EMBO J 1998; 17: 667-676.
19. Sugiyama K, Sugiura K, Hara T, et al. Aurora-B associated protein phosphatases as negative regulators of kinase activation. Oncogene 2002; 21: 3103-3111.
20. Yasui Y, Urano T, Kawajiri A, et al. Autophosphorylation of a newly identified site of Aurora-B is indispensable for cytokinesis. J Biol Chem 2004; 279: 12997-13003.
21. Wei Q, Xia Y. Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem 2006; 281: 21652-21659.
22. Luo J, Shen G, Yan J, et al. AtCHIP functions as an E3 ubiquitin ligase of protein phosphatase 2A subunits and alters plant response to abscisic acid treatment. Plant J 2006; 46: 649-657.
23. Wickstrom SA, Masoumi KC, Khochbin S, et al. CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. EMBO J 2010; 29: 131-144.
24. Brush MH, Guardiola A, Connor JH, et al. Deactylase inhibitors disrupt cellular complexes containing protein phosphatases and deacetylases. J Biol Chem 2004; 279: 7685-7691.
25. Park JH, Jong HS, Kim SG, et al. Inhibitors of histone deacetylases induce tumor-selective cytotoxicity through modulating Aurora-A kinase. J Mol Med 2008; 86: 117-128.
26. Pierre P, Scheel J, Rickard JE, et al. CLIP-170 links endocytic vesicles to microtubules. Cell 1992; 70: 887-900.
27. Vaughan PS, Miura P, Henderson M, et al. A role for regulated binding of p150(Glued) to microtubule plus ends in organelle transport. J Cell Biol 2002; 158: 305-319.
28. Saito K, Kigawa T, Koshiba S, et al. The CAP-Gly domain of CYLD associates with the proline-rich sequence in NEMO/IKKgamma. Structure (Cambridge) 2004; 12: 1719-1728.
29. Fu J, Bian M, Jiang Q, et al. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007; 5: 1-10.
30. Katayama H, Brinkley WR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003; 22: 451-464.